Search results
Our employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself. ABOUT ABBVIE.
AbbVie was founded in 2013 when we became a separate company from Abbott. Our name represents a proud connection to that legacy. AbbVie formed a new kind of enterprise – a biopharmaceutical company – with the stability, global scale, resources and commercial capabilities of a pharmaceutical company and the focus and culture of a biotech.
AbbVie Patient Access Support includes programs that provide access and financial support and treatment-related resources to patients. We can help identify financial assistance options to support patients in accessing prescribed AbbVie medications, including eligibility for myAbbVie Assist.
AbbVie supports independent education for experienced healthcare providers and scientists studying current, new and emerging science. new patients supported by our patient support programs in 2021. patients and healthcare providers reached through our independent healthcare grants in 2022. From drug discovery and development to ensuring our ...
May 7, 2024 · At AbbVie, we partner to achieve two important outcomes: to deliver innovative medicines and to make a remarkable impact on people’s lives. We start with a highly integrated approach to developing and sustaining our partnerships. We work as one connected unit with a commitment to establishing collaborations across the development continuum ...
Nov 30, 2023 · About AbbVie in Oncology. At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of tumor types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines.
Feb 12, 2024 · AbbVie has acquired all outstanding ImmunoGen common stock for $31.26 per share. It is expected that ImmunoGen's common stock will cease to trade on the NASDAQ stock exchange prior to market open on February 12, 2024. AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly ...
